Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||E7449 + Temozolomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|E7449||2X-121||PARP Inhibitor (Pan) 19 Tankyrase Inhibitor 9||E7449 (2X-121) binds to and inhibits PARP1 and PARP2, as well as TNKS1 and TNKS2, potentially resulting in increased sensitivity to DNA damaging agents and decreased growth of tumor cells with defective DNA damage repair (PMID: 26513298, PMID: 32523090).|
|Temozolomide||Temodar||Methazolastone||Chemotherapy - Alkylating 14||Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||E7449 + Temozolomide||Preclinical||Actionable||In a preclinical study, the combination of E7449 and Temodar (temozolomide) inhibited tumor growth in mouse melanoma models, with increased efficacy compared to either agent alone (PMID: 26513298).||26513298|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|